A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.
Study of an Investigational Study Drug for Airway Inflammation in COPD
Study Overview
LPS18583 is a multinational, randomized, double-blind, placebo-controlled, parallel-group, Phase 4 study with 2 treatment groups. The purpose of this study is to assess the effect of dupilumab compared with placebo on airway inflammation, resistance, and remodeling including mucus plugging and its association with improvement on lung function, exacerbations, and quality of life improvement in participants aged 40 years of age up to 85 years of age (inclusive).
Study details include:
The study duration will be up to 40 weeks. The treatment duration will be up to 24 weeks. The number of visits will be 9.
Eligibility Criteria
You may be eligible for this study if you meet the following criteria:
- Conditions: Chronic Obstructive Pulmonary Disease
-
Age: 40 years - 85 years
-
Gender: All
Inclusion Criteria:
Participants with a physician diagnosis of Chronic Obstructive Pulmonary Disease (COPD) who meet the following criteria at screening:
- Current or former smokers with a smoking history of ≥10 pack-years
- Moderate-to-severe COPD (post-BD FEV1/FVC ratio <0.70 and post-BD FEV1 % predicted >30% and ≤70%)
- Medical Research Council Dyspnea Scale grade ≥2 or COPD assessment test (CAT) score ≥10
- Global Initiative for Chronic Obstructive Lung Disease (GOLD) category E , Frequent or severe exacerbations
- Background triple therapy (ICS + LABA + LAMA) for 3 months before randomization with a stable dose of medication for ≥1 month before Visit 1; dual therapy (LABA + LAMA) allowed if ICS is contraindicated
- Evidence of Type 2 inflammation: Participants with blood eosinophils ≥300 cells/μL at screening or with blood eosinophils ≥150 cells/μL at Visit 1 (screening) and with a history of blood eosinophils ≥300 cells/μL within the past year during stable state (non-exacerbation).
- Mucus score cutoff of ≥3
Exclusion Criteria:
- A current diagnosis of asthma according to the Global Initiative for Asthma diagnostic (GINA) guidelines, or documented history of asthma
- Significant pulmonary disease other than COPD (eg, lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts
- Treatment with oxygen >4.0 L/min for ≥8 hours/day Respiratory tract infection within 4 weeks before screening, or during the screening period
- Diagnosis of α-1 anti-trypsin deficiency
- Any biologic therapy (including experimental treatments and dupilumab)
- Participants on treatment with mucolytics unless on stable therapy for >6 months
The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.
The purpose of this research study is to learn about the effects of an investigational study drug on airway inflammation (swelling and irritation in the breathing tubes) in adults ages 40 to 85 with moderate to severe chronic obstructive pulmonary disease (COPD) who have frequent or severe COPD flare-ups.
Participants will receive either the investigational study drug or a placebo. A placebo looks like the investigational study drug but does not contain active medication. The study will compare how these options affect airway inflammation and related lung problems.
Who can participate:
Adults ages 40 to 85 with COPD may be able to participate if they:
- Have COPD and are a current or former smoker with a long-term smoking history
- Have moderate to severe COPD with ongoing shortness of breath or COPD symptoms
- Have had frequent or severe COPD flare-ups
- Have been using standard COPD inhaler treatment with three types of medicines for at least three months (or two types if they cannot use inhaled steroids)
- Have blood test results showing a type of inflammation linked to higher eosinophils (a kind of white blood cell)
- Have mucus plugging based on a study scoring method
Study timeline and visits:
Participation lasts up to 40 weeks. There will be 9 study visits.
Find a study site near you
,
Send a message
Enter your contact details to connect with study team
Primary Contact
Please choose between Voice or SMS based delivery of verification code
or